Phase II Pilot, Prospective, Open Label, Multicenter CT, to Evaluate the Safety and Efficacy of PF299804, a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation

Trial Profile

Phase II Pilot, Prospective, Open Label, Multicenter CT, to Evaluate the Safety and Efficacy of PF299804, a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2016

At a glance

  • Drugs Dacomitinib (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Aug 2016 Planned End Date changed from 1 Oct 2015 to 1 Dec 2016.
    • 11 Aug 2015 Planned End Date changed from 1 Jul 2015 to 1 Oct 2015, as reported by ClinicalTrials.gov.
    • 11 Aug 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Aug 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top